Skip to main content
SpringerLink
Log in

Malignant Hyperthermia

  • Chapter
  • First Online:
Neuromuscular Urgencies and Emergencies

  • 440 Accesses

Abstract

Malignant hyperthermia is considered as a life-threatening hypermetabolic crisis resulting from exposure to volatile anesthetic agents and depolarizing muscle relaxants. The sequel of event followed by the exposure to these triggers results in massive release of the calcium ions in the skeletal muscle resulting in sustained muscle contraction. The symptoms include hyperventilation, tachycardia, tachypnea, hyperthermia to acidosis, hypercapnia, and even rhabdomyolysis. The introduction of dantrolene has resulted in significant improvement in mortality associated with MH. This chapter aims to discuss the genetic factors associated with MH, the typical clinical presentation along with the diagnostic criteria, and appropriate management protocol used in case of malignant hyperthermia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Cardiac Arrests and Deaths Associated with Malignant Hyperthermia in North America from 1987 to 2006: A Report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesthesiology. 2008;108:603–11. https://doi.org/10.1097/ALN.0b013e318167aee2.

    Article  PubMed  Google Scholar 

  2. Halliday NJ. Malignant hyperthermia. J Craniofac Surg. 2003;14(5):800–2.

    Article  Google Scholar 

  3. Ording H. Incidence of malignant hyperthermia in Denmark. Anesth Analg. 1985;64(7):700–4.

    CAS  PubMed  Google Scholar 

  4. Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118(2):381–7. https://doi.org/10.1213/ANE.0b013e3182937d8b.

    Article  CAS  PubMed  Google Scholar 

  5. Brady JE, Sun LS, Rosenberg H, Li G. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001–2005. Anesth Analg. 2009;109(4):1162–6. https://doi.org/10.1213/ane.0b013e3181ac1548.

    Article  PubMed  Google Scholar 

  6. Strazis KP, Fox AW. Malignant hyperthermia: a review of published cases. Anesth Analg. 1993;77(2):297–304.

    Article  CAS  Google Scholar 

  7. Voermans NC, Snoeck M, Jungbluth H. RYR1-related rhabdomyolysis: a common but probably underdiagnosed manifestation of defective skeletal muscle ryanodine receptor dysfunction. Rev Neurol. 2016;172:546–58. https://doi.org/10.1016/j.neurol.2016.07.018.

    Article  CAS  PubMed  Google Scholar 

  8. Carpenter D, Ringrose C, Leo V, Morris A, Robinson RL, Halsall PJ, et al. The role of CACNA1S in predisposition to malignant hyperthermia. BMC Med Genet. 2009;10:104. https://doi.org/10.1017/S0003480000008186.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Robinson RL, Curran JL, Ellis FR, Halsall PJ, Hall WJ, Hopkins PM, et al. Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann Hum Genet. 2000;64(Pt 4):307–20.

    Article  CAS  Google Scholar 

  10. Stamm DS, Powell CM, Stajich JM, Zismann VL, Stephan DA, Chesnut B, et al. Novel congenital myopathy locus identified in native American Indians at 12q13.13–14.1. Neurology. 2008;71:1764–9. https://doi.org/10.1212/01.wnl.0000325060.16532.40.

    Article  CAS  PubMed  Google Scholar 

  11. Schneider banger D, Johannsen S, Roewer N, et al. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag. 2014;10:355–62. https://doi.org/10.2147/TCRM.S47632.

    Article  CAS  Google Scholar 

  12. Glahn KP, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines fromt he European Malignant Hyperthermia Group. Br J Anaesth. 2010;105:417–20. https://doi.org/10.1093/bja/aeq243.

    Article  CAS  Google Scholar 

  13. Lawal TA, Todd JJ, Meilleur KG. Ryanodine receptor 1-related myopathies: diagnostic and therapeutic approaches. Neurotherapeutics. 2018;15(4):885–99. https://doi.org/10.1007/s13311-018-00677-1. Review.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Guis S, Figarella-Branger D, Monnier N, Bendahan D, Kozak-Ribbens G, Mattei JP, et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol. 2004;61:106–13. https://doi.org/10.1001/archneur.61.1.106.

    Article  PubMed  Google Scholar 

  15. Stamm DS, Powell CM, Stajich JM, Zismann VL, Stephan DA, Chesnut B, et al. Novel congenital myopathy locus identified in Native American Indians at 12q13.13–14.1. Neurology. 2008;71:1764–9. https://doi.org/10.1212/01.wnl.0000325060.16532.40.

    Article  CAS  PubMed  Google Scholar 

  16. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771–9. https://doi.org/10.1097/00000542-199404000-00008.

    Article  CAS  PubMed  Google Scholar 

  17. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br J Anaesth 1984; 56(11):1267–9.

    Google Scholar 

  18. Larach MG, Landis JR, Bunn JS, Diaz M. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry. Anesthesiology. 1992;76(1):16–27.

    Article  CAS  Google Scholar 

  19. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand. 1997;41(8):955–66. https://doi.org/10.1111/j.1399-6576.1997.tb04820.x.

    Article  CAS  PubMed  Google Scholar 

  20. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology. 1998;88(3):579–88.

    Article  CAS  Google Scholar 

  21. Stowell KM. DNA testing for malignant hyperthermia: the reality and the dream. Anesth Analg. 2014;118(2):397–406. https://doi.org/10.1213/ANE.0000000000000063.

    Article  CAS  PubMed  Google Scholar 

  22. Broman M, Kleinschnitz I, Bach JE, Rost S, Islander G, Muller CR. Next-generation DNA sequencing of a Swedish malignant hyperthermia cohort. Clin Genet. 2015;88(4):381–5. https://doi.org/10.1111/cge.12508.

    Article  CAS  PubMed  Google Scholar 

  23. Bannister RA. Dantrolene-induced inhibition of skeletal L-type Ca2+ current requires RyR1 expression. Biomed Res Int. 2013;2013:390493. https://doi.org/10.1155/2013/390493.

    Article  CAS  PubMed  Google Scholar 

  24. Malignant Hyperthermia Association of the United States; 2017. https://www.mhaus.org/healthcare-professionals/managing-a-crisis/.

  25. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010;110(2):498–507. https://doi.org/10.1213/ANE.0b013e3181c6b9b2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Missouri Healthcare, Columbia, MO, USA

    Harleen Kaur & Karim George Salame

Authors
  1. Harleen Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karim George Salame
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harleen Kaur .

Editor information

Editors and Affiliations

  1. Department of Neurology, University of Missouri, Columbia, MO, USA

    Niraj Arora

  2. Department of Neurology, University of Missouri, Columbia, MO, USA

    Raghav Govindarajan

  3. Department of Neurology, University of Missouri, Columbia, MO, USA

    Saurabh Kataria

  4. Department of Neurology, University of Missouri, Columbia, MO, USA

    Premkumar Nattanmai Chandrasekaran

Rights and permissions

Reprints and permissions

Copyright information

© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaur, H., Salame, K.G. (2020). Malignant Hyperthermia. In: Arora, N., Govindarajan, R., Kataria, S., Nattanmai Chandrasekaran, P. (eds) Neuromuscular Urgencies and Emergencies. Springer, Cham. https://doi.org/10.1007/978-3-030-53145-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53145-4_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53144-7

  • Online ISBN: 978-3-030-53145-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation